Literature DB >> 6147547

Clinical findings and serological evidence of HTLV-III infection in homosexual contacts of patients with AIDS and persistent generalised lymphadenopathy in London.

B G Gazzard, D C Shanson, C Farthing, A G Lawrence, R S Tedder, R Cheingsong-Popov, A Dalgleish, R A Weiss.   

Abstract

Between 1980 and 1984 28 homosexual men who had had ano-genital intercourse with patients with either acquired immunodeficiency syndrome (AIDS) or persistent generalised lymphadenopathy (PGL) were followed up. The pattern of the sexual links indicated that within this group there were two clusters, one consisting of 7 men and the other of 13.17 of the 28 contacts became ill with either AIDS or PGL; among those in the clusters, 4 died of AIDS and 11 had PGL, and of the rest 2 had PGL. 16 of the 19 men in the clusters who were tested for HTLV-III antibodies were seropositive, as were 7 of those not in the clusters. 111 men attending a genitourinary medicine clinic who had not had known contact with either AIDS or PGL patients and who were being screened for syphilis served as controls. Of these, 19/86 who were homosexual and 0/25 who were heterosexual were positive for HTLV-III antibodies. None of the 4 who died of AIDS had had contact with each other. The 2 in the first cluster seemed to have been linked by a symptomless HTLV-III-negative man, who was also probably the link between the two clusters, while in the second cluster the chief "carrier" seemed to be a seropositive man in whom PGL developed. These findings are consistent with the hypothesis that HTLV-III is the sexually transmitted causative agent of AIDS and PGL.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147547     DOI: 10.1016/s0140-6736(84)92563-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

1.  Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany.

Authors:  G Hunsmann; J Schneider; H Bayer; R Kurth; A Werner; H D Brede; V Erfle; W Mellert; H R Brodt; L Bergmann
Journal:  Klin Wochenschr       Date:  1985-03-01

2.  Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein.

Authors:  J J Wang; S Steel; R Wisniewolski; C Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

3.  Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III.

Authors:  L E Henderson; R Sowder; T D Copeland; S Oroszlan; L O Arthur; W G Robey; P J Fischinger
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

4.  Factors affecting seropositivity to human T cell lymphotropic virus type III (HTLV-III) or lymphadenopathy associated virus (LAV) and progression of disease in sexual partners of patients with AIDS.

Authors:  J N Weber; A McCreaner; E Berrie; J Wadsworth; D J Jeffries; A J Pinching; J R Harris
Journal:  Genitourin Med       Date:  1986-06

Review 5.  HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention.

Authors:  Rebecca F Baggaley; Richard G White; Marie-Claude Boily
Journal:  Int J Epidemiol       Date:  2010-04-20       Impact factor: 7.196

6.  High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states.

Authors:  L S Kaminsky; T McHugh; D Stites; P Volberding; G Henle; W Henle; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

7.  Lymphadenopathy and antibodies to HTLV-III in homosexual men. Clinical, laboratory and epidemiological features.

Authors:  U Bienzle; I Guggenmoos-Holzmann; K Zwingenberger; R Thommsen; K Ritter; A Uy; H Bayer; J Schneider; G Hunsmann; C H Coester
Journal:  Klin Wochenschr       Date:  1985-07-01

8.  Subregions of a conserved part of the HIV gp41 transmembrane protein are differentially recognized by antibodies of infected individuals.

Authors:  U Certa; W Bannwarth; D Stüber; R Gentz; M Lanzer; S Le Grice; F Guillot; I Wendler; G Hunsmann; H Bujard
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

9.  Tax-1 and Tax-2 similarities and differences: focus on post-translational modifications and NF-κB activation.

Authors:  Margret Shirinian; Youmna Kfoury; Zeina Dassouki; Hiba El-Hajj; Ali Bazarbachi
Journal:  Front Microbiol       Date:  2013-08-15       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.